# EDGAR Filing Document

**Accession Number:** 0001374339
**File Stem:** 0001104659-26-064545
**Filing Date:** 2026-5
**Character Count:** 10341
**Document Hash:** 93e91c37039572bea1563fafe26aed0e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-064545.hdr.sgml**: 20260520

**ACCESSION NUMBER**: 0001104659-26-064545

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260520

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260520

**DATE AS OF CHANGE**: 20260520

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ProMIS Neurosciences Inc.
- **CENTRAL INDEX KEY:** 0001374339
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41429
- **FILM NUMBER:** 261004466

**BUSINESS ADDRESS:**
- **STREET 1:** SUITE 200, 1920 YONGE STREET
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M4S 3E2
- **BUSINESS PHONE:** 416-847-6898

**MAIL ADDRESS:**
- **STREET 1:** SUITE 200, 1920 YONGE STREET
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M4S 3E2

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMORFIX LIFE SCIENCES LTD
- **DATE OF NAME CHANGE:** 20060831

?xml version='1.0' encoding='ASCII'? PROMIS NEUROSCIENCES INC._May 20, 2026

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 20, 2026**

## PROMIS NEUROSCIENCES INC.
**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Ontario, Canada** | **001-41429** | **98-0647155** |
| **(State or other jurisdiction**<br>**of incorporation)** | **(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification No.)** |

---

---

| | |
|:---|:---|
| **Suite 200, 1920 Yonge Street,** <br>**Toronto, Ontario** | **M4S 3E2** |
| **(Address of principal executive**<br>**offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (416) 847-6898**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol(s)** | **Name of Each Exchange on Which Registered** |
| Common Shares, no par value per share | PMN | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

As further described in Item 5.07 below, the stockholders of ProMIS Neurosciences Inc. (the "***Company***") approved an amendment (the "2025 Plan Amendment") to the Company's 2025 Stock Option and Incentive Plan (the "***2025 Plan***") at the Company's 2026 Annual Meeting of Stockholders (the "***Annual Meeting***") held on May 20, 2026. The 2025 Plan Amendment was previously approved by the Company's Board of Directors (the "***Board***"). The 2025 Plan Amendment, which became effective upon the stockholders' approval at the Annual Meeting, increases the number of Common Shares (as defined below) available for issuance thereunder the 2025 Plan by 900,000 Common Shares.

A description of the 2025 Plan Amendment is included in Proposal 3 of the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 9, 2026 (the "***Proxy Statement***"), which summary is incorporated in its entirety herein by reference. The descriptions of the 2025 Plan Amendment contained herein and in the Proxy Statement do not purport to be complete and are subject to, and qualified in their entirety by reference to, the full text of the 2025 Plan Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On May 20, 2026, the Company held its Annual Meeting. The shareholders considered three proposals, each of which is described in more detail in the Company's Proxy Statement. Of the 8,967,693 Common Shares, no par value per share (the "***Common Shares***"), outstanding as of the record date, 4,762,024 Common Shares, or approximately 53.1%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of shareholders at the Annual Meeting.

**Proposal No. 1**: Election of seven nominees to serve as directors until the 2027 annual meeting of shareholders or until his or her successor has been duly elected and qualified or until his or her earlier resignation or removal. The votes were cast as follows by holders of Common Shares:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name** | **Votes For** | **Votes For** | **Votes Withheld** | **Votes Withheld** |
| Eugene Williams |  | 4,108,919 |  | 38,462 |
| Neil Cashman, M.D. |  | 4,143,889 |  | 3,492 |
| Joshua Mandel-Brehm |  | 4,118,276 |  | 29,105 |
| Maggie Shafmaster, Ph.D., J.D. |  | 4,143,725 |  | 3,656 |
| Neil K. Warma |  | 4,103,311 |  | 44,070 |
| William Wyman |  | 4,109,684 |  | 37,697 |
| Slanix Alex, Pharm.D |  | 4,122,179 |  | 25,202 |

---

Broker non-votes: 614,643.

All seven nominees were elected.

**Proposal No. 2:** Ratification of the appointment of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows by holders of Common Shares:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Votes For** | **Votes Against** | **Votes Against** | **Abstained** | **Abstained** |
| Ratification of appointment of Baker Tilly US, LLP | 4,657,634 |  | 4,415 |  | 99,975 |

---

Broker non-votes: 0.

**Proposal No. 3**: An ordinary resolution approving the Amendment to the 2025 Stock Option and Incentive Plan to increase the number of Common Shares available for issuance thereunder by 900,000 Common Shares.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Votes For** | **Votes Against** | **Votes Against** | **Abstained** | **Abstained** |
| Approval of the Amendment to the 2025 Stock Option and Incentive Plan | 3,352,388 |  | 774,193 |  | 20,800 |

---

Broker non-votes: 614,643.

No other matters were submitted to or voted on by the Company's shareholders at the Annual Meeting.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1 | [Amendment No. 1 to the ProMIS Neurosciences Inc. 2025 Stock Option and Incentive Plan](pmn-20260520xex10d1.htm) |
| 104 | Cover Page Interactive Data File (embedded within Inline XBRL document) |

---

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **PROMIS NEUROSCIENCES INC.** | **PROMIS NEUROSCIENCES INC.** |
| Date: May 20, 2026 | By: | /s/ Neil Warma |
|  |  | Name: Neil Warma |
|  |  | Title: Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**AMENDMENT NO. 1** 

**TO THE** 

**PROMIS NEUROSCIENCES, INC.** 

**2025 STOCK OPTION AND INCENTIVE PLAN** 

**WHEREAS**, Promis Neurosciences, Inc. (the "Company") maintains the Promis Neurosciences, Inc. 2025 Stock Option and Incentive Plan (the "Plan"), which was previously adopted by the Board of Directors of the Company (the "Board") and approved by the stockholders of the Company;

**WHEREAS**, the Board desires to amend the Plan to increase the number of shares available for issuance under the Plan;

**WHEREAS**, Section 16 of the Plan provides that the Board may amend the Plan at any time, subject to certain conditions set forth therein; and

**WHEREAS**, this Amendment will become effective upon approval by the Company's stockholders at the Company's 2026 Annual Meeting and if, for any reason, the Company's stockholders fail to approve this Amendment, the existing Plan shall continue in full force and effect.

**NOW, THEREFORE**:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Section 3(a) of the Plan is hereby amended by deleting "117,868" where it appears in the first sentence thereof and replacing it with "1,017,868."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Effective Date of Amendment</u>. This Amendment to the Plan shall become effective upon the date that it is approved by the Company's stockholders in accordance with applicable laws and regulations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Other Provisions.</u> Except as set forth above, all other provisions of the Plan shall remain unchanged.

IN WITNESS WHEREOF, this Amendment No. 1 to the Plan has been adopted by the Board of Directors of the Company on April 2, 2026 and approved by the stockholders of the Company on May 20, 2026.

------